Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
Immune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). In particular, anti-programmed-death (ligand) 1 antibodies were approved for the treatment of triple-negative breast cancer (TNBC), both in first line for metastatic disease and in neoadjuvant setting,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359221146129 |
| _version_ | 1797938238202052608 |
|---|---|
| author | Carmine Valenza Graziella Rizzo Maria Ilenia Passalacqua Laura Boldrini Chiara Corti Dario Trapani Giuseppe Curigliano |
| author_facet | Carmine Valenza Graziella Rizzo Maria Ilenia Passalacqua Laura Boldrini Chiara Corti Dario Trapani Giuseppe Curigliano |
| author_sort | Carmine Valenza |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). In particular, anti-programmed-death (ligand) 1 antibodies were approved for the treatment of triple-negative breast cancer (TNBC), both in first line for metastatic disease and in neoadjuvant setting, on the basis of a demonstrated improvement of the survival outcomes. In light of these results, current clinical trials aim at improving this benefit investigating novel combinations and strategies, at exploring the role of ICIs beyond TNBC, and at better selecting the patients in order to spare non-responders from avoidable toxicities. This narrative review aims at summarizing and discussing the evolving landscape of immunotherapeutic treatments for BC, highlighting the current challenges and the future perspectives. |
| first_indexed | 2024-04-10T18:57:37Z |
| format | Article |
| id | doaj.art-270c304f22f740c2852ebf058959c8cd |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-10T18:57:37Z |
| publishDate | 2023-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-270c304f22f740c2852ebf058959c8cd2023-01-31T16:04:10ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592023-01-011510.1177/17588359221146129Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectivesCarmine ValenzaGraziella RizzoMaria Ilenia PassalacquaLaura BoldriniChiara CortiDario TrapaniGiuseppe CuriglianoImmune checkpoint inhibitors (ICIs) deeply changed the treatment landscape of breast cancer (BC). In particular, anti-programmed-death (ligand) 1 antibodies were approved for the treatment of triple-negative breast cancer (TNBC), both in first line for metastatic disease and in neoadjuvant setting, on the basis of a demonstrated improvement of the survival outcomes. In light of these results, current clinical trials aim at improving this benefit investigating novel combinations and strategies, at exploring the role of ICIs beyond TNBC, and at better selecting the patients in order to spare non-responders from avoidable toxicities. This narrative review aims at summarizing and discussing the evolving landscape of immunotherapeutic treatments for BC, highlighting the current challenges and the future perspectives.https://doi.org/10.1177/17588359221146129 |
| spellingShingle | Carmine Valenza Graziella Rizzo Maria Ilenia Passalacqua Laura Boldrini Chiara Corti Dario Trapani Giuseppe Curigliano Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives Therapeutic Advances in Medical Oncology |
| title | Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives |
| title_full | Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives |
| title_fullStr | Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives |
| title_full_unstemmed | Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives |
| title_short | Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives |
| title_sort | evolving treatment landscape of immunotherapy in breast cancer current issues and future perspectives |
| url | https://doi.org/10.1177/17588359221146129 |
| work_keys_str_mv | AT carminevalenza evolvingtreatmentlandscapeofimmunotherapyinbreastcancercurrentissuesandfutureperspectives AT graziellarizzo evolvingtreatmentlandscapeofimmunotherapyinbreastcancercurrentissuesandfutureperspectives AT mariaileniapassalacqua evolvingtreatmentlandscapeofimmunotherapyinbreastcancercurrentissuesandfutureperspectives AT lauraboldrini evolvingtreatmentlandscapeofimmunotherapyinbreastcancercurrentissuesandfutureperspectives AT chiaracorti evolvingtreatmentlandscapeofimmunotherapyinbreastcancercurrentissuesandfutureperspectives AT dariotrapani evolvingtreatmentlandscapeofimmunotherapyinbreastcancercurrentissuesandfutureperspectives AT giuseppecurigliano evolvingtreatmentlandscapeofimmunotherapyinbreastcancercurrentissuesandfutureperspectives |